Watch FBIOP. Know when insiders buy.
One email the day a filing lands. Free.
FBIOP
Fortress Biotech, Inc.
18.45
−0.13 −0.67%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
96
PASS · shorts 96
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.5BP/E 7.0DIV YIELD —FCF YIELD —REV TTM $68.5M +15.5%NET INCOME $111.8MNET CASH $161.6M52W 6.53 – 21.08SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $18.7M | +14.0% | 67.2% | −$10M | −$468K | −103.0% | -0.08 | −$59.3M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $16M | +22.1% | 61.2% | −$7.7M | $110.4M | — | 2.82 | $203.9M | — | — | May 14 |
| Q4 2025 · Dec 31derived | $16.1M | +6.3% | 66.2% | −$4.8M | −$3.9M | — | -0.21 | −$12.5M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | $17.6M | +20.5% | 67.4% | −$6.8M | $5.8M | — | 0.11 | −$6.1M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | $16.4M | +10.2% | 69.9% | −$36.5M | $15.5M | — | 0.45 | −$27.6M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $13.1M | +0.8% | 63.5% | −$22.3M | −$10.6M | — | -0.48 | −$19.6M | — | — | May 14 |
| Q4 2024 · Dec 31derived | $15.1M | −24.2% | 69.0% | −$23.8M | −$6.8M | — | -0.26 | −$12.9M | $0 | −$12.9M | Mar 31 |
| Q3 2024 · Sep 30 | $14.6M | −57.9% | 69.4% | −$22.1M | −$12.9M | — | -0.76 | −$20.1M | $0 | −$20.1M | Nov 14 |
| Q2 2024 · Jun 30 | $14.9M | — | 61.6% | −$27.8M | −$10.9M | — | -0.73 | −$21.8M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $13M | — | 53.9% | −$36.6M | −$15.4M | — | -1.04 | −$25.4M | — | — | May 15 |
| Q4 2023 · Dec 31derived | $19.9M | — | 88.7% | −$19.6M | −$9.3M | — | -0.53 | −$34.9M | $28K | −$35M | Mar 31 |
| Q3 2023 · Sep 30 | $34.8M | — | 81.5% | −$13.8M | −$5M | — | -0.94 | −$16.8M | $1K | −$16.8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $63.3M | 66.9% | −$70.2M | $6.8M | 10.8% | -0.07 | −$65.8M | — | — | — | $664K |
| FY2024 · to Dec 31 | $57.7M | 63.8% | −$110.4M | −$46M | -79.8% | -2.69 | −$80.2M | $0 | −$80.2M | — | $694K |
| FY2023 · to Dec 31 | $84.5M | 72.9% | −$142.3M | −$60.6M | -71.7% | -8.47 | −$128.2M | $63K | −$128.3M | — | $736K |
| FY2022 · to Dec 31 | $75.7M | 59.4% | −$203.6M | −$86.6M | -114.3% | -15.97 | −$179.4M | $2.7M | −$182.1M | — | $749K |
| FY2021 · to Dec 31 | $68.8M | 53.4% | −$188.5M | −$64.7M | -94.1% | -0.79 | −$116.5M | $4.6M | −$121.1M | — | $749K |
| FY2020 · to Dec 31 | $45.6M | 68.0% | −$94.3M | −$46.5M | -102.0% | -0.65 | −$83.7M | $1.9M | −$85.6M | $70K | $237K |
Every number comes from Fortress Biotech, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.